Gan & Lee Pharmaceuticals.

This study tests a new injectable medicine, GZR101-80, for people with type 2 diabetes that is not well controlled by current pills or basal insulin. About 345 adults will receive the drug for 16 weeks to see if it lowers blood sugar and HbA1c safely. The goal is better daily con…

This study tests an injection called GZR18 in 140 obese adults with moderate-to-severe obstructive sleep apnea who already use a breathing machine (PAP). The goal is to see if the drug improves breathing during sleep, reduces weight, and boosts quality of life compared to a place…

This study tests an injection called GZR18 in 140 obese adults with moderate to severe obstructive sleep apnea who cannot or will not use a CPAP machine. The goal is to see if the drug improves breathing during sleep and helps with weight loss over 52 weeks. Participants will rec…

This early-stage trial is testing an experimental drug called GLR2037 in 65 men with metastatic prostate cancer that has spread to bones or soft tissues. The main goals are to check the drug's safety and how the body processes it. Participants will take GLR2037 daily in 28-day cy…

This early-stage trial will check whether two different ways of making the experimental drug GZR4 produce the same levels in the blood. About 64 healthy men will receive a single shot of one version or the other. The study is not designed to treat diabetes, but to ensure future b…

This early-stage trial will test whether a new injection called GLR1044 works like the approved drug Dupixent in the body. About 198 healthy Chinese men will receive a single dose of either GLR1044 or Dupixent. Researchers will compare how the drugs are absorbed and processed, an…